End Brain Cancer Initiative Releases Guide on Next-Generation Sequencing
News related to:End Brain Cancer Initiative · 2 min read
End Brain Cancer Initiative has released a new guide aimed at helping patients, caregivers, and healthcare providers understand the role of Next-Generation Sequencing (NGS) in the diagnosis and treatment of cancerous brain tumors. This initiative, formerly known as the Chris Elliott Fund, is dedicated to ensuring that patients with brain cancer have access to advanced diagnostics and treatments.
The guide, available at endbraincancer.org/next-generation-sequencing, explains that NGS is a powerful laboratory technology that reads the genetic code of a patient’s tumor. By identifying specific mutations, alterations, or biomarkers in the DNA or RNA of cancer cells, doctors can match patients to treatments designed to target these changes. This personalized approach can significantly improve treatment outcomes and patient care.
Kari Schroeder, the Nurse Navigator/Clinical Trial Coordinator at End Brain Cancer Initiative, is available to provide further information.
Servier, a global leader in oncology, has also contributed to this initiative. The company invests close to 20% of its revenue from brand-name medicines in research and development (R&D), underscoring its commitment to advancing targeted therapies. This investment is part of Servier’s broader strategy to identify mutations and understand how they impact cancer and its progression, ultimately aiming to help the right patients find the right treatment at the right time.
The End Brain Cancer Initiative is a 501(c)3 non-profit patient advocacy organization focused on disease education, awareness, and outreach. Its mission is to increase patient access and improve the standard of care for those diagnosed with brain cancer, brain tumors, or metastatic disease to the brain. The organization partners with industry, patients, researchers, advocacy groups, medical teams, hospital networks, and others to educate patients and their caregivers, empowering them to have informed conversations with their medical teams.
For those interested in supporting the End Brain Cancer Initiative’s mission, donations can be made at endbraincancer.org. The organization’s commitment to providing immediate access to advanced diagnostics, treatments, specialists, and clinical trial participation is crucial in offering the best hope for survival and sustained quality of life to patients.
The release highlights the importance of collaboration between organizations like End Brain Cancer Initiative and companies like Servier in advancing the field of oncology. By leveraging the latest technologies and investing in research, these entities are working towards improving the lives of patients diagnosed with brain cancer.